X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!
















Authors
 

The curious case of Wockhardt - II

(Jun 21, 2011)

This series of 2 articles describes the fall of Wockhardt from its peak in 2008 and its current situation.

Wockhardt: Europe led 2004

(Feb 10, 2005)

Domestic pharma company, Wockhardt, recently declared its December quarter as well as full year numbers. In 4QCY04, the company's consolidated revenues clocked a buoyant 21% growth led by strong performance in Europe and rest of the world. Its bottomline growth was equally buoyant at 26% YoY. The company ended the full year with over 31% revenue and nearly 50% bottomline growth.

Wockhardt: Sustainability is the key

(Oct 21, 2004)

Domestic pharma company, Wockhardt, has declared its 3QCY04 and 9mCY04 results. In 3QCY04, the company's topline grew by 11.3% led by decent show of its European operations. The bottomline grew by 13.6%, basically led by expansion of operating margins by nearly 4%.

Wockhardt: The insulin story

(Sep 23, 2003)

In line with the general market sentiment, Wockhardt has been steadily gaining in the past few months. The key reason for this upswing in Wockhardt’s stock price has been the launch of human insulins (branded as ‘Wosulin’) by the company. Wockhardt has thus become Asia’s first and the world’s fourth producer of human recombinant insulin. But how big is this news and what could be its implications on the future revenues of the company. Let’s find out.

Pharma: Quarter under review

(Aug 19, 2003)

After a lackluster performance in March quarter pharma companies made a remarkable turnaround in the June quarter. While the domestic pharma companies recorded strong revenue growth on the back of a revival in the anti-infectives segment, the MNC pharma companies managed to successfully control costs resulting in higher margins. In this context, let us briefly understand the performance of the industry as a whole during the June quarter.

Wockhardt: Good times ahead

(Aug 6, 2003)

Domestic pharma major, Wockhardt has declared its 2QFY04 results recently. After witnessing a poor first quarter, the company has reported a marginal 5% increase in the topline and a 13% increase in the bottomline. For 1HFY04, the company has recorded a stagnant topline and a 20% drop in the bottomline. In this context, let us briefly examine the performance of the company during 2QFY04.

Wockhardt: Going international

(Jul 15, 2003)

Wockhardt Ltd, a subsidiary of Khorakiwala Holdings and Investments Pvt. Ltd, is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and growing focus on biotechnology. The company derives 62% of its revenues from the domestic markets. However, with the recent acquisitions in the international markets, the company has demonstrated its growing interest in exports. Wockhardt has also started increasing its R&D focus and has made investments of Rs 460

Wockhardt: Growing the inorganic way

(Jul 10, 2003)

Wockhardt is one of the leading domestic pharma companies with strong focus on the biotechnology sector for future growth. The company derives 62% of its revenues from the domestic market. However, off late, with increased competition and lower growth being witnessed in the domestic markets, Wockhardt has started to focus on exports. The company adopting the inorganic growth method for increasing exports had acquired Wallis Ltd in 1998.

Wockhardt: Swift growth

(Oct 31, 2002)

Wockhardt has posted another quarter of strong growth in revenues and improvement in operating margins. For 3QFY02, the company’s revenues were up 19%, while the bottomline grew by 22%.

Wockhardt: Swift progress

(Jul 30, 2002)

Wockhardt Ltd. has declared encouraging results for 1HFY03. While sales have grown by more than 20%, net profit forged ahead by 37%. The impressive performance in sales is on the back of strong growth in export formulations and key brands in the domestic market.

Wockhardt: Strong performance

(Apr 29, 2002)

Wockhardt Ltd. has declared encouraging results for 1QFY03. While sales have grown by more than 27%, net profit forged ahead by 37%. The impressive performance in sales is on the back of strong growth in export formulations and key brands in the domestic market. The peformance of the company is above our expectations of 20% growth.

Wockhardt: R&D picks momentum

(Apr 2, 2002)

Yesterday Wockhardt announced that the first molecule (WCK-771) from its research pipeline has entered in to Phase-I of clinical trials in India. WCK-771 is an anti-infective molecule used in the treatment of sepsis. The company has already started exploring opportunities for out licensing the molecule.

Vaccines Market: Needs a booster

(Mar 9, 2002)

The global vaccine business has experienced considerable growth and innovation over the past decade with preventive healthcare gaining importance. As explained in our earlier report on vaccines, these drugs are basically antigenic preparation used to stimulate the production of antibodies and procure immunity from one or several diseases. Though the segment is logging attractive growth rates, it faces problems in terms of getting enough R&D attention.

Wockhardt: On an expansion mode

(Mar 9, 2002)

Wockhardt, the Rs 6.5 bn biotech pioneer in India seems to be on a major expansion drive with a clear growth strategy. While the company seems to have missed out on the generics boom, the export strategy, going forward, seems quite clear. The company is aiming to create global class capacities in some niche product categories.

Wockhardt: Impressive performance

(Feb 12, 2002)

Wockhardt Ltd has declared encouraging results for FY02. While sales have grown by more than 16%, net profit forged ahead by 43% to more than a Rs 1 bn. This was mainly on the back of an impressive 300 basis points rise in operating margins. However, interest cost shot up considerably to Rs 38 m. On a consolidated basis, sales for the quarter grew by 14% to Rs 2 bn while profits grew by 37%.

Wockhardt: R&D efforts kick start

(Nov 22, 2001)

Recently, Wockhardt announced filing application for conducting clinical trials on its anti-infective molecule, WCK-771.The company’s R&D initiative started some four years back. Though at a very early stage these seem to be bearing fruit.

Wockhardt: Exports propels growth

(Oct 30, 2001)

Wockhardt Ltd has declared encourgaging results for 3QFY02. While sales grew by 15% to 1,724 m, net profit forged ahead by 35% to Rs 300 m. Operating margins improved by 300 basis points. However, interest cost shot up considerably to Rs 38 m. On a consolidated basis, sales for the quarter grew by 14% to Rs. 193 crores while Profits grew by 37%.

Wockhardt: Exports drive growth

(Jul 30, 2001)

Wockhardt has declared a better than expected results for 1HFY02. While sales increased by 16%, net profit zoomed by 39%. The rise in net profit was on the back of 280 basis points improvement in operating margins and substantial savings in interest costs.

Vaccines Market: An overview

(Jun 7, 2001)

The pharmaceutical market worldwide is shifting focus from curative to preventive healthcare and vaccines are playing an increasingly important role. Vaccines are basically antigenic preparation used to stimulate the production of antibodies and procure immunity from one or several diseases. Worldwide, pharmaceutical companies are concentrating on engineered vaccines of international standards with high purity, efficacy and tolerability with no major side effects with the help of biotechnology.

Merind amalgamation buoys Wockhardt topline

(Feb 22, 2001)

Wockhardt has announced a 28.5% growth in net profit on the back of a 34% growth in its topline for the year ended December 2000. During the year the company amalgamated Merind's business and merged Wockhardt Veterinary into the company. The company has not specified as to the contribution of these in the company's topline growth.


Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS